The Melanoma and Skin Cancer Steering Committee (MSCSC) addresses the design, prioritization, and evaluation of concepts for phase 2, 2/3, and 3 clinical trials in melanoma and skin cancer. Committee activities help foster collaboration between groups and institutions engaged in conducting trials. The MSCSC's membership comprises NCTN group representatives, community oncologists, Specialized Programs of Research Excellence (SPORE) representatives, biostatisticians, patient advocates, subject matter experts, and NCI staff.
Chair
Alexander N. Shoushtari, M.D.
Memorial Sloan Kettering Cancer Center
New York, NY
Members
Carmen Allegra, M.D.
National Cancer Institute
Bethesda, MD
Marcus O. Butler, M.D.
University of Toronto Princess Margaret Cancer Centre
Toronto, ON, Canada
Gary C. Doolittle, M.D.
University of Kansas Cancer Center
Westwood, KS
Neil Gross, M.D., FACS
University of Texas MD Anderson Cancer Center
Houston, TX
Tina J. Hieken, M.D.
Mayo Clinic
Rochester, MN
John R. Hyngstrom, M.D.
Rush University Medical Center
Chicago, IL
Edward L. Korn, Ph.D.
National Cancer Institute
Bethesda, MD
Nicole Kounalakis, M.D.
Northside Cancer Institute
Atlanta, GA
Sandra Lee, Sc.D.
Dana-Farber Cancer Institute
Boston, MA
Janice M. Mehnert, M.D.
New York University Langone Health
New York, NY
Margaret M. Mooney, M.D., M.B.A.
National Cancer Institute
Bethesda, MD
Sapna Patel, M.D.
University of Colorado
Aurora, CO
Teresa Petrella, M.D., M.S.
Sunnybrook Health Sciences Centre
Toronto, ON, Canada
Chris B. White
Mucosal Melanoma Survivor LLC
Melissa, TX
Jedd D. Wolchok, M.D., Ph.D.
Weill Cornell Medicine
New York, NY
Michael C. Wu, Ph.D.
Fred Hutchinson Cancer Center
Seattle, WA
Hassan Zarour, M.D.
University of Pittsburgh Medical Center
Pittsburgh, PA
NCI CCCT Program Director
Elena Schwartz, Ph.D., M.S.
elena.schwartz@nih.gov